Advances in malaria chemotherapy

Abstract

The present report provides advice on the use of drugs for the suppression and treatment of malaria taking into account the presence of drug-resistant parasites and on the best ways in which existing and new antimalarials may be used to counter the further development and spread of such resistance. The development, clinical assessment, and future deployment of the new drug, mefloquine, have received special attention. Emphasis is placed on the need for standardized techniques for testing parasite sensitivity by in vitro and in vivo methods, and on the efficient conduct and monitoring of clinical trials.